AbbVie: Humira Competition Has Gone ‘Exceptionally Well’ For Us
Biosimilars Struggle To Capture Large Volumes In US; Brand Erosion Is Mainly Price
With adalimumab biosimilars slow to capture market share from Humira in the US, AbbVie says that erosion for the top-selling brand is continuing to go “exceptionally well” for the originator.
